Quidel Corp. (NASDAQ:QDEL) announced that it has signed aworldwide license and joint collaboration agreement withEpitope Inc. (ASE:EPT) to develop a new line of fertilitydiagnostic tests that will use oral samples.
Quidel of San Diego will license Epitope's oral specimencollection technology to combine with its own Generation IIIone-step test technology.
Quidel intends the resulting products to complement its line ofConceive urine-based one-step tests by providing consumerswith saliva-based rapid tests for fertility hormones.
(c) 1997 American Health Consultants. All rights reserved.